Structured evidence table for L-Carnitine Exercise Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| L-Carnitine Exercise Performance Randomized Trial | Aim This review aims to provide an integrated synthesis that bridges mechanistic evidence (anti-inflammatory, antioxidant) with clinical outcomes (mortality, arrhythmias) for LC supplementation in CAD, while critically appraising inconsistencies across the literature (e.g., heart failure, reinfarction). | 1 | Werida RH (2026) | Therapeutic potential of L-carnitine in coronary artery disease: a systematic review. |
| L-Carnitine Exercise Performance Randomized Trial | Results Across mechanistic endpoints, LC was associated with reductions in inflammatory markers, oxidative stress indices, and cardiac injury biomarkers, with several trials noting improvements in left-ventricular function and lipid profiles. | 1 | Werida RH (2026) | Therapeutic potential of L-carnitine in coronary artery disease: a systematic review. |
| L-Carnitine Exercise Performance Randomized Trial | Background Coronary artery disease (CAD) persists as a major global health burden, contributing significantly to both morbidity and mortality rates worldwide, mostly attributable to atherosclerosis and oxidative stress. | 1 | Werida RH (2026) | Therapeutic potential of L-carnitine in coronary artery disease: a systematic review. |
| L-Carnitine Exercise Performance Randomized Trial | L-carnitine (LC), a natural derivative of amino acid, plays a critical role in mitochondrial fatty acid transport and has demonstrated potential antioxidant as well as anti-inflammatory effects. | 1 | Werida RH (2026) | Therapeutic potential of L-carnitine in coronary artery disease: a systematic review. |
| L-Carnitine Exercise Performance Randomized Trial | 1 Aging is characterized by progressive physiological decline, including loss of skeletal muscle mass and function (Sarcopenia), reduced mitochondrial efficiency, and increased oxidative stress, all of which contribute to frailty and diminished quality of life in older adults (). | 3 | Wang Xiaolan (2026) | Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults |
| L-Carnitine Exercise Performance Randomized Trial | 1 2 3 4 5 By the age of 70, individuals may experience a 25%−30% reduction in muscle mass, which is strongly associated with impaired mobility, falls, and loss of independence (). | 3 | Wang Xiaolan (2026) | Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults |
| L-Carnitine Exercise Performance Randomized Trial | Low circulating glycine levels have been associated with insulin resistance, obesity, and higher cardiometabolic risk (,). | 3 | Wang Xiaolan (2026) | Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults |
| L-Carnitine Exercise Performance Randomized Trial | In this review, the term “older adults” generally refers to individuals aged ≥60 or ≥65 years, consistent with definitions used by the World Health Organization and most geriatric clinical trials. | 3 | Wang Xiaolan (2026) | Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults |
Source documents